TY - JOUR
T1 - Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome
AU - Yue, Gang
AU - Hao, Suyang
AU - Fadare, Oluwole
AU - Baker, Stephen
AU - Pozdnyakova, Olga
AU - Galili, Naomi
AU - Woda, Bruce A.
AU - Raza, Azra
AU - Wang, Sa A.
PY - 2008/4
Y1 - 2008/4
N2 - Hypocellular myelodysplastic syndrome (MDS) represents only a small portion of MDS, of which, the clinical significance has not been well-defined. By using currently accepted age-adjusted criteria to define hypocellularity as <30% in patients <70 years old, and <20% in >70 years old, we identified 163 (15.5%) hypocelluar MDS from 1049 consecutive adult MDS patients over an 11-year period (1995-2006). Compared to normal/hypercellular MDS, hypocellular MDS patients were younger (p < 0.01), less anemic (p = 0.02), but more neutropenic (p < 0.001) and thrombocytopenic (p = 0.05), and had a comparable cytogenetic risk group distribution (p = 0.09) and international prognostic scores (IPSS, p = 0.13). With a median follow-up of 52 months, hypocellular MDS showed a favorable overall survival (56 months versus 28 months, log-rank p < 0.0001) over normal/hypocellular MDS, and this survival preference was also demonstrated in all IPSS groups and cytogenetic risk groups, and was independent of all other risk factors (Cox regression test, p = 0.01). In conclusion, our study demonstrated that hypocellular MDS has characteristic clinicopathologic features, and bone marrow hypocellularity in MDS is an independent factor which predicts a favorable outcome.
AB - Hypocellular myelodysplastic syndrome (MDS) represents only a small portion of MDS, of which, the clinical significance has not been well-defined. By using currently accepted age-adjusted criteria to define hypocellularity as <30% in patients <70 years old, and <20% in >70 years old, we identified 163 (15.5%) hypocelluar MDS from 1049 consecutive adult MDS patients over an 11-year period (1995-2006). Compared to normal/hypercellular MDS, hypocellular MDS patients were younger (p < 0.01), less anemic (p = 0.02), but more neutropenic (p < 0.001) and thrombocytopenic (p = 0.05), and had a comparable cytogenetic risk group distribution (p = 0.09) and international prognostic scores (IPSS, p = 0.13). With a median follow-up of 52 months, hypocellular MDS showed a favorable overall survival (56 months versus 28 months, log-rank p < 0.0001) over normal/hypocellular MDS, and this survival preference was also demonstrated in all IPSS groups and cytogenetic risk groups, and was independent of all other risk factors (Cox regression test, p = 0.01). In conclusion, our study demonstrated that hypocellular MDS has characteristic clinicopathologic features, and bone marrow hypocellularity in MDS is an independent factor which predicts a favorable outcome.
KW - Cytogenetics
KW - Hypocellular
KW - IPSS risk groups
KW - Myelodysplastic syndrome
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=39149083040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39149083040&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2007.08.006
DO - 10.1016/j.leukres.2007.08.006
M3 - Article
C2 - 17888511
AN - SCOPUS:39149083040
SN - 0145-2126
VL - 32
SP - 553
EP - 558
JO - Leukemia Research
JF - Leukemia Research
IS - 4
ER -